During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with l ...

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish ...

Immunotherapy is the form of treatment that redirects the immune system toward a pathogen or disease. In many cases, ...

The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study that uses a pioneering ...

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) shared new and updated results from its RESET clinical development ...

Cabaletta Bio (CABA) announced new and updated clinical data from the first 10 patients dosed with resecabtagene autoleucel, or rese-cel, ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology company specializing in the development of allogeneic CAR T cell therapies, stands at a critical juncture in its journey to bring innovative ...

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision ...

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to ...